April 17th 2025
No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
High Bone Mineral Density Associated With More Than a Doubling of Breast Cancer Risk
December 1st 1996Long-term exposure to estrogen, as measured by bone mineral density, can more than double the risk of breast cancer, according to a study led by researchers at the University of Pittsburgh and reported in the November 5th issue of The Journal of the American Medical Association. Estrogen replacement therapy is often prescribed in women during menopause to reduce hot flashes and other uncomfortable symptoms of this transitional period.
Breast Cancer Group Recommends Return Of Funds, in Attempt To Limit its Focus
December 1st 1996WASHINGTON--In an extraordinary decision, the steering committee of the National Action Plan on Breast Cancer (NAPBC) voted to reject nearly the entire $14.75 million that Congress provided it for use in fiscal year 1997.
Factor Analysis of New Symptom Scale in Breast Cancer Finds Six Clusters
November 27th 1996WAYNE, NJ-Initial testing of the Symptom Experience Scale (SES), designed to measure women's experiences of symptoms associated with treatment for breast cancer, found six factors that used all 24 SES items and accounted for 83% of the variance, report Nelda Samarel, EdD, RN, of William Paterson College of New Jersey, and her colleagues.
New Breast Cancer Patient Resource Is Available
November 1st 1996WILMINGTON, Del-The Breast Cancer Patient Education Service, recently established by Zeneca Pharmaceuticals, allows breast cancer patients and their families to obtain patient education materials on tamoxifen (Nolvadex) with one phone call.
Indigent Women With Breast Cancer Are Often Not Referred for Breast Reconstruction
November 1st 1996The option of reconstruction after mastectomy for breast cancer is often not discussed with indigent patients, according to a study presented at the 65th Annual Meeting of the American Society of Plastic and Reconstructive Surgeons (ASPRS) held in Dallas, Texas.
Klausner Cites Breast Cancer Progress in Jo Oberstar Lecture
November 1st 1996WASHINGTON--Breast cancer mortality continues to drop among white women in the United States, Canada, and Great Britain, and, for the first time, it has dropped in black American women, NCI Director Richard Klausner said in his delivery of the 6th Annual Jo Oberstar Memorial Lecture at the George Washington University School of Medicine.
Workplace Cancer Screening Program Saves Lives, Money
November 1st 1996NEW YORK-Screening for breast cancer in the workplace saves money as well as lives, according to a study commissioned by Zeneca Inc. To emphasize this important message to business, the results were presented in a news conference held on Wall Street at the New York Stock Exchange.
NIH to Evaluate New Data on Breast Cancer Screening in Younger Women
November 1st 1996BETHESDA, Md-NIH plans a consensus development conference to assess the most recent data on the efficacy of mammography in screening women age 40 to 49 for breast cancer. The agency plans to convene the conference on January 21-23, 1997, on the NIH Bethesda campus.
DNA Squencing Locates p53 Mutations in Breast Cancer
November 1st 1996NEW YORK-DNA sequencing is the gold standard for determining the presence or absence of p53 mutations in breast tumors, said Jorge A. Leon, PhD, corporate director for biotechnology research and development, Corning Nichols Institute/Corning Clinical Laboratories.
Book Profiles 32 Women Who Fought Breast Cancer
October 1st 1996BIRMINGHAM, Ala--In 1994, the Comprehensive Cancer Center of the University of Alabama at Birmingham commissioned photojournalist Melissa Springer to create an exhibit celebrating breast cancer survivors. Her finished project has now been published as A Tribe of Warrior Women.
New RIA Blood Test Predicts Breast Cancer Recurrence
October 1st 1996CHICAGO--The Truquant BR RIA blood test (manufactured by Biomira Diagnostics, Inc.) has been shown to be a highly specific predictor of recurrent breast cancer. In clinical trials, positive test results predicted relapse 83% of the time, providing as much as a 12-month (average, 5 month) warning over clinical symptoms and/or other diagnostic methods for breast cancer recurrence.
New Cancer Gene Marker Could Help Tailor Chemotherapy for Breast Cancer
October 1st 1996Researchers at Duke University Comprehensive Cancer Center have found that a newly identified liver cancer gene is also defective in more aggressive breast tumors that may not respond to certain common types of chemotherapy.
Media Attention to Prostate Cancer Lags Behind Breast Cancer, Advocate Says
October 1st 1996NEW YORK--Michael Korda, best-selling author and editor-in-chief and vice president of Simon and Schuster, had never heard of PSA until a routine test showed that his was elevated; he had never thought about prostate cancer as something that could happen to him. After all, he was asymptomatic, a "fanatic exerciser," had given up smoking 20 years ago, and ate carefully.
Women, Kids from the Heartland Express Feelings about Breast Cancer
October 1st 1996OKLAHOMA CITY--Project Wo-man, a committee of the American Cancer Society (ACS)--has published a book depicting the experiences of Oklahoma women with breast cancer as expressed by the women themselves, their friends, children, and other loved ones through stories, photographs, and artwork (see illustrations at right and on page 1).
Kopans Receives the Kushner Writing Award
October 1st 1996BETHESDA, Md--Daniel B. Kopans, MD, of the Department of Radiology, Massachusetts General Hospital and Harvard Medical School, has received the 1996 Rose Kushner Award for Writing Achievement in the Field of Breast Cancer for best scientific article.
Tamoxifen Prevention Study Enrollment Nears Completion
October 1st 1996BETHESDA, Md--The Breast Cancer Prevention Trial (BCPT), launched in 1992, will need fewer women than originally estimated for completion. Although planned for 16,000 women, the trial now has more than 12,000 enrolled, and needs only another 1,000 for completion, which is expected next year.
Assessing Women's Potential Risk of Developing Breast Cancer
October 1st 1996This well-written article can benefit only from reinforcement of a few of its major points, some supplemental discussion about the important role of biologic models in understanding and managing breast cancer development, and a note about the critical need for research and perspectives from the social sciences concerning this subject. I say "only" because this article beautifully and clearly explores some of the language of epidemiology critical to the subject, language which is becoming increasingly important in routine medical practice. Practitioners and, increasingly, the public (medical "consumers") are concerned with risks and numbers.
Optimal Duration of Tamoxifen Requires More Investigation
October 1st 1996An expert panel of nine international cancer researchers and practicing oncolo-gists met in Boston to discuss the past, present, and future uses of antiestrogens in the treatment of breast cancer. This article represents the first in a series of reports based on the symposium presentations that will be featured in subsequent issues of Oncology News International.The symposium was sponsored by Zeneca Pharmaceuticals.
Amy Langer on Leave of Absence From NABCO After Automobile Accident
October 1st 1996NEW YORK--Amy S. Langer, of the National Alliance of Breast Cancer Organizations (NABCO), has taken a leave of absence from her position as executive director, due to extensive injuries suffered in a serious car accident in upstate New York.
M.D. Anderson Unveils Mammography Van
October 1st 1996HOUSTON--Just in time for Breast Cancer Awareness Month, The University of Texas M.D. Anderson Cancer Center has unveiled a mobile mam-mography program that will bring screening mammography to corporate and community locations throughout the Houston area.
AgeAwareness Group Urges the Media to Keep Breast Cancer Issues on the Public Agenda
September 1st 1996NEW YORK--Public discussion has played a large part in the recent declines in breast cancer mortality, say the sponsors of National Breast Cancer Awareness Month (NBCAM), and they urge the media to keep breast cancer on the public agenda.
FDA Clears Aredia for Use in Treating Bone Metastases of Breast Cancer
September 1st 1996ROCKVILLE, Md--The FDA has cleared Chiron Therapeutics' Aredia (pamidronate disodium for injection) for the treatment of patients with osteolytic bone metastases of breast cancer, in conjunction with standard antineoplastic therapy.
Mandated ABMT Coverage May Not Lead to More Procedures
September 1st 1996PHILADELPHIA--A Massachusetts study suggests that legislation requiring insurers and HMOs to cover high-dose chemotherapy/autologous bone marrow or stem cell transplantation for metastatic breast cancer does not lead to significant increases in the number of procedures performed.
Health Insurance: Coverage of Autologous Bone Marrow Transplantation for Breast Cancer
September 1st 1996Rapid advances in biomedical research and technology are producing a continuous stream of new, and often expensive, medical devices, drugs, and therapies. Health insurers' decisions about whether and when to provide coverage for these new
Study Advocates Breast Ultrasound Screening as an Adjunct to Mammography
August 1st 1996With improved instrumentation and scanning techniques, breast ultrasound screening is earning a prominent role in the detection of breast cancer in women with dense breasts when no lump is felt and no abnormalities are detected on the
NCI Says Long-Awaited Long Island Breast Cancer Study Now Underway
August 1st 1996BETHESDA, Md--The Long Island Breast Cancer Study Project, ordered by Congress in 1993, is now underway under the auspices of the NCI and the National Institute of Environmental Health Sciences. The study will attempt to determine whether pollutants (pesticides and other chemical irritants) are linked to the area's excessive breast cancer rates.